UBS maintains Kodiak Sciences at Buy, raises price target to $150 from $120

What happened

UBS maintained its Buy rating on Kodiak Sciences and raised its price target to $150 from $120. UBS said the new target was 25.0% higher and implied 38.6% upside from Kodiak Sciences’ Nov. 12 closing price of $108.25.

Confirmed

Global impact / market context

The higher target signals that UBS sees more potential value in Kodiak Sciences shares than before, while keeping its Buy rating unchanged. If investors act on that view, buying could support demand for the stock; the target is an analyst estimate, not a guaranteed future price.

Analyst inference

The supplied update reports one broker’s view and gives no company results, clinical developments, or wider industry evidence to explain the higher target. The stated upside compares the target with a past closing price, so it does not establish how the shares will perform next.

Analyst inference

What to watch

1. Look for later UBS updates that either reaffirm or revise the $150 target; a change would show whether the analyst’s view of Kodiak Sciences’ value is shifting. Analyst inference
2. Watch for company or clinical developments in later reporting that could clarify whether Kodiak Sciences’ prospects support the higher target; none are described in this update. Analyst inference
3. Compare future share prices with the $150 target and the cited $108.25 Nov. 12 close; the article provides no later trading data or evidence of investor response. Analyst inference

Evidence

• Original source link unavailable